Financial cycles of acquisition and ‘buybacks’ threaten public access to breakthrough drugs

https://www.sciencedaily.com/releases/2016/07/160727194358.htm

An analysis of a new drug’s journey to market shines a light on financial practices that see some major pharmaceutical companies relying on a cycle of acquisitions, profits from high prices, and shareholder-driven maneuvers that threatens access to medicines for current and future patients.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s